Oncolysin B

Drug Profile

Oncolysin B

Alternative Names: Anti-B4-bR; Anti-CD19-bR; B4 blocked ricin

Latest Information Update: 08 Nov 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Developer ImmunoGen; Massachusetts General Hospital; Nonindustrial source
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Immunosuppressants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Leukaemia; Lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Nov 1999 A phase II study has been added to the therapeutic trials and pharmacodynamics sections
  • 02 Sep 1998 A study has been added to the therapeutic trials section
  • 20 Mar 1997 Discontinued-II for Leukaemia in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top